ErbB Surface Receptor Complexes as Biomarkers
    1.
    发明申请
    ErbB Surface Receptor Complexes as Biomarkers 审中-公开
    ErbB表面受体复合物作为生物标志物

    公开(公告)号:US20100291594A1

    公开(公告)日:2010-11-18

    申请号:US12689144

    申请日:2010-01-18

    IPC分类号: G01N33/574

    CPC分类号: G01N33/56905 G01N33/6893

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    ErbB surface receptor complexes as biomarkers
    2.
    发明申请
    ErbB surface receptor complexes as biomarkers 审中-公开
    ErbB表面受体复合物作为生物标志物

    公开(公告)号:US20050130238A1

    公开(公告)日:2005-06-16

    申请号:US11041041

    申请日:2005-01-21

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Methods for detecting receptor complexes comprising PI3K
    3.
    发明授权
    Methods for detecting receptor complexes comprising PI3K 有权
    用于检测包含PI3K的受体复合物的方法

    公开(公告)号:US07648828B2

    公开(公告)日:2010-01-19

    申请号:US11041073

    申请日:2005-01-21

    IPC分类号: G01N33/574

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Surface Receptor Complexes as Biomarkers
    4.
    发明申请
    Surface Receptor Complexes as Biomarkers 审中-公开
    表面受体复合物作为生物标志物

    公开(公告)号:US20090111127A1

    公开(公告)日:2009-04-30

    申请号:US11866293

    申请日:2007-10-02

    IPC分类号: G01N33/574 C12Q1/02 G01N33/53

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含细胞表面膜受体二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的一种或多种细胞表面膜受体的二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症的状态的方法,包括存在或不存在 癌前状态,癌症状态的存在或不存在,癌症的预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Methods for detecting receptor complexes comprising PI3K
    5.
    再颁专利
    Methods for detecting receptor complexes comprising PI3K 有权
    用于检测包含PI3K的受体复合物的方法

    公开(公告)号:USRE44437E1

    公开(公告)日:2013-08-13

    申请号:US13352705

    申请日:2012-01-18

    IPC分类号: G01N33/574

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Methods for Detecting Receptor Complexes Comprising PI3K
    6.
    发明申请
    Methods for Detecting Receptor Complexes Comprising PI3K 有权
    检测包含PI3K的受体复合物的方法

    公开(公告)号:US20050170439A1

    公开(公告)日:2005-08-04

    申请号:US11041073

    申请日:2005-01-21

    摘要: Abstract of the Disclosure The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 摘要揭示本发明涉及一种包含ErbB细胞表面膜受体二聚体的患者样品中的一类新生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症的状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    ERBB HETERODIMERS AS BIOMARKERS
    7.
    发明申请
    ERBB HETERODIMERS AS BIOMARKERS 审中-公开
    ERBB HETERODIMERS作为生物标记

    公开(公告)号:US20080187948A1

    公开(公告)日:2008-08-07

    申请号:US11965659

    申请日:2007-12-27

    IPC分类号: C12Q1/02 G01N33/50

    摘要: A method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more heterodimers of ErbB, or Her, cell surface membrane receptors measured directly in a patient sample is described. The invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more heterodimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 描述了通过将这样的条件与直接在患者样品中测量的ErbB或Her的细胞表面膜受体的一个或多个异源二聚体的量相关联来确定疾病状态或健康状况的方法。 本发明包括通过将样品细胞中ErbB细胞表面膜受体的一个或多个异源二聚体的量的测量值与这样的状态相关联来确定来自个体的样本中癌症的状态的方法,包括存在或不存在前体 - 癌症状态,癌症状态的存在或不存在,癌症的预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Methods for Detecting Receptor Complexes Comprising PDGFR
    8.
    发明申请
    Methods for Detecting Receptor Complexes Comprising PDGFR 审中-公开
    检测包含PDGFR的受体复合物的方法

    公开(公告)号:US20050170438A1

    公开(公告)日:2005-08-04

    申请号:US11041029

    申请日:2005-01-21

    摘要: Abstract of the Disclosure The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 摘要揭示本发明涉及一种包含ErbB细胞表面膜受体二聚体的患者样品中的一类新生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Detecting and profiling molecular complexes
    9.
    发明授权
    Detecting and profiling molecular complexes 有权
    检测和分析分子复合物

    公开(公告)号:US08198031B2

    公开(公告)日:2012-06-12

    申请号:US11717760

    申请日:2007-03-12

    摘要: Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.

    摘要翻译: 提供了用于检测样品(例如细胞或组织裂解物)中分子复合物(特别是蛋白质)的形成的方法。 在一个方面,提供了对复合物中的第一种蛋白质特异性的切割探针和一种或多种特异于复合物中的一种或多种第二种蛋白质的结合化合物。 在结合时,诱导切割探针以产生仅在切割探针的局部区域中切割附着于结合化合物的分子标签的活性物质,例如单线态氧。 将释放的分子标签与测定混合物和彼此分离,以提供与复合物中存在的蛋白质的数量和类型相关的读数。

    Profiling frequencies of receptor heterodimers
    10.
    发明授权
    Profiling frequencies of receptor heterodimers 有权
    受体异源二聚体的分布频率

    公开(公告)号:US07135300B2

    公开(公告)日:2006-11-14

    申请号:US10830543

    申请日:2004-04-22

    IPC分类号: G01N33/53

    摘要: Methods are provided for detecting formation of oligomeric complexes of molecules on the surface of cell membranes. These methods employ pairs of tagged probes and cleaving probes, each of which binds specificly to a cell surface molecule. The tagged probe includes a molecular tag that is linked to a first binding compound through a cleavable linkage, and the cleaving probe includes a second binding agent and a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to cell surface molecules that have formed an oligomeric complex results in release of the molecular tag from the binding compound, providing a measure of formation of the complex.

    摘要翻译: 提供了用于检测细胞膜表面上分子的寡聚复合物的形成的方法。 这些方法采用成对的标记探针和切割探针,每个探针和细胞表面分子都特异性地结合。 标记的探针包括通过可切割键连接到第一结合化合物的分子标签,并且所述切割探针包括第二结合剂和切割诱导部分,其在限定的接近于其内时可切割连接。 两个探针与形成寡聚复合物的细胞表面分子的结合导致分子标签从结合化合物的释放,提供复合物形成的量度。